Inhaled nitric oxide in pediatric cardiac surgery

International Anesthesiology Clinics

Volumn 42, Issue 4, 2004, Pages 93-100

  Kawakami, Hiromasa ^a   Ichinose, Fumito ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; ZAPRINAST;

CHILD; CONGENITAL HEART DISEASE; DIAGNOSTIC VALUE; DRUG MECHANISM; DRUG POTENTIATION; GREAT VESSELS TRANSPOSITION; HEART CATHETERIZATION; HEART LEFT RIGHT SHUNT; HEART VENTRICLE SEPTUM DEFECT; HIGH RISK PATIENT; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; LUNG VASCULAR RESISTANCE; LUNG VEIN DRAINAGE ANOMALY; METHEMOGLOBINEMIA; PATENT DUCTUS ARTERIOSUS; PEDIATRIC ANESTHESIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; CARDIAC SURGICAL PROCEDURES; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; POSTOPERATIVE COMPLICATIONS; VASODILATION;

EID: 6344268973     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-200404240-00010     Document Type: Review

References (44)

1. Brown KL, Ridout DA, Goldman AP, et al. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med. 2003;31:28-33.
2. Rabinovitch M, Haworth SG, Castaneda AR, et al. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation. 1978;58:1107-1122.
3. Wessel DL, Adatia I, Giglia TM, et al. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation. 1993;88:2128-2138.
4. Bando K, Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg. 1996;112:1600-1607.
5. Schulze-Neick I, Penny DJ, Rigby ML, et al. L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery. Circulation. 1999;100:749-755.
6. Rybalkin SD, Yan C, Bornfeldt KE, et al. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003;93:280-291.
7. Cannon RO III, Schechter AN, Panza JA, et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest. 2001;108:279-287.
8. Roberts JD Jr, Lang P, Bigatello LM, et al. Inhaled nitric oxide in congenital heart disease. Circulation. 1993;87:447-453.
9. Goldman AP, Delius RE, Deanfield JE, et al. Pharmacological control of pulmonary blood flow with inhaled nitric oxide after the fenestrated Fontan operation. Circulation. 1996;94:II44-II48.
10. Russell IA, Zwass MS, Fineman JR, et al. The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease. Anesth Analg. 1998;87:46-51.
11. Miller OI, Tang SF, Keech A, et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomized double-blind study. Lancet. 2000;356:1464-1469.
12. Journois D, Pouard P, Mauriat P, et al. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg. 1994;107:1129-1135.
13. Roberts JD Jr, Polaner DM, Lang P, et al. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340:818-819.
14. Kinsella JP, Neish SR, Shaffer E, et al. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340:819-820.
15. Hayward CS, Rogers P, Keogh AM, et al. Inhaled nitric oxide in cardiac failure: vascular versus ventricular effects. J Cardiovasc Pharmacol. 1996;27:80-85.
16. Fullerton DA, Jones SD, Jaggers J, et al. Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation. J Thorac Cardiovasc Surg. 1996;111:753-762.
17. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
18. Atz AM, Adatia I, Lock JE, et al. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol. 1999;33:813-819.
19. Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation. 2002;106:I76-I81.
20. Waldman JD. From PediHeart: inhaled nitric oxide-In clinical trial or in clinical practice? Pediatr Cardiol. 2000;21:274.
21. Adatia I, Atz AM, Jonas RA, et al. Diagnostic use of inhaled nitric oxide after neonatal cardiac operations. J Thorac Cardiovasc Surg. 1996;112:1403-1405.
22. Beghetti M, Morris K, Cox P, et al. Inhaled nitric oxide differentiates pulmonary vasospasm from vascular obstruction after surgery for congenital heart disease. Intensive Care Med. 1999;25:1126-1130.
23. Ichinose F, Adrie C, Hurford WE, et al. Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs. J Appl Physiol. 1995;78:1288-1295.
24. Ichinose F, Erana-Garcia J, Hromi J, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med. 2001;29:1000-1005.
25. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.
26. Lepore JJ, Maroo A, Pereira NL, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol. 2002;90:677-680.
27. Schulze-Neick I, Hartenstein P, Li J, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation. 2003;108(suppl 1): II167-II173.
28. Stocker C, Penny DJ, Brizard CP, et al. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med. 2003;29:1996-2003.
29. Adrie C, Holzmann A, Hirani WM, et al. Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome. Anesthesiology. 2000;93:422-430.
30. Ichinose F, Adrie C, Hurford WE, et al. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology. 1998;88:410-416.
31. Ichinose F, Erana-Garcia J, Hromi J, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med. 2001;29:1000-1005.
32. Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-405.
33. Ravichandran LV, Johns RA, Rengasamy A. Direct and reversible inhibition of endothelial nitric oxide synthase by nitric oxide. Am J Physiol. 1995;268:H2216-H2223.
34. Frank DU, Horstman DJ, Morris GN, et al. Regulation of the endogenous NO pathway by prolonged inhaled NO in rats. J Appl Physiol. 1998;85:1070-1078.
35. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999;91:307-310.
36. Frampton MW, Morrow PE, Cox C, et al. Effects of nitrogen dioxide exposure on pulmonary function and airway reactivity in normal humans. Am Rev Respir Dis. 1991;143:522-527.
37. NIOSH recommendations for occupational safety and health standards 1998. MMWR Morb Mortal Wkly Rep. 1988;37:1-29.
38. Clutton-Brock J. Two cases of poisoning by contamination of nitrous oxide with higher oxides of nitrogen during anaesthesia. Br J Anaesth. 1967;39:388-392.
39. Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci. 2001;59:5-16.
40. Kinsella JP, Truog WE, Walsh WF, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr. 1997;131:55-62.
41. Roberts JD Jr, Fineman JR, Morin FC III, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med. 1997;336:605-610.
42. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 1998;26:15-23.
43. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics. 1997;99:838-845.
44. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology. 1999;91:1090-1121.